Application 209293
- Type
- ANDA
- Sponsor
- SCIECURE PHARMA INC
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | PAROXETINE HYDROCHLORIDE | PAROXETINE HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | EQ 12.5MG BASE | No | No |
| 002 | PAROXETINE HYDROCHLORIDE | PAROXETINE HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | EQ 25MG BASE | No | No |
| 003 | PAROXETINE HYDROCHLORIDE | PAROXETINE HYDROCHLORIDE | TABLET, EXTENDED RELEASE;ORAL | EQ 37.5MG BASE | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 42858-703 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-703 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-703 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-705 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-705 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-705 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-707 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-707 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 42858-707 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Rhodes Pharmaceuticals L.P. | ANDA | Current |
| 63629-9498 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Bryant Ranch Prepack | ANDA | Current |
| 63629-9499 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Bryant Ranch Prepack | ANDA | Current |
| 63629-9500 | PAROXETINE | PAROXETINE HYDROCHLORIDE HEMIHYDRATE | Bryant Ranch Prepack | ANDA | Current |